Treatment procedures and response in patients treated with CPX-351. (A) Timeline of treatment procedures. (B) Range and median reduction in BM cellularity and blasts after treatment with CPX-351. (C) BM biopsy findings for Patient 7 at diagnosis of AML with MDS-related changes and hyperinflammation (panels i-iii) and 1 month after a single cycle of CPX-351 (panel iv). (i) Hypercellular marrow with sheets of dysplastic megakaryocytes (hematoxylin and eosin [H&E] stain; original magnification ×200). (ii) Increased immature mononuclear cells, normal hematopoiesis absent (H&E stain; original magnification ×600). (iii) Reticulin fibrosis (reticulin stain; original magnification ×400). (iv) Hypocellular marrow with no dysplastic cells or fibrosis (H&E stain; original magnification ×600). FLAG, fludarabine, cytarabine, granulocyte colony-stimulating factor regimen; T-ALL, T-cell acute lymphoblastic leukemia.